CELYAD ONCOLOGY SA

Analyst Reco. Celyad Oncology SA

Equities

CYAD

BE0974260896

Real-time Euronext Bruxelles Other stock markets 04:29:01 2024-04-30 am EDT			5-day change	1st Jan Change
0.315 ^EUR	-4.55%		-4.55%	-19.23%

Apr. 04	Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Feb. 09	Celyad Oncology Seeks Termination of Reporting Obligations to US SEC	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HC Wainwright Downgrades Celyad Oncology Neutral From Buy, Shares Plunge 12% at Midday Trading	22-02-28	MT
Wells Fargo Adjusts Celyad Oncology's Price Target to $11 from $20, Keeps Overweight Rating	22-01-11	MT
Wall Street Set for Narrow Gains, US Unemployment Rate Falls in November	21-12-03	MT
CELYAD ONCOLOGY : HC Wainwright Adjusts Celyad Oncology's Price Target to $15 From $17, Maintains Buy Rating	21-08-06	MT
CELYAD ONCOLOGY : JonesTrading Downgrades Celyad Oncology to Hold from Buy	21-03-26	MT
CELYAD ONCOLOGY : HC Wainwright Adjusts Celyad Oncology's Price Target to $18 From $22, Keeps Buy Rating	20-12-08	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019

Replicate our performance

fermer